Skip Ribbon Commands
Skip to main content
Skip over global navigation links
U.S. Department of Health and Human Services

BARDA funds advanced development of drug to treat injuries from exposure to cyanide

Date: August 30, 2011

Company: Southwest Research Institute of San Antonio

Contract amount: $4.4 million over 15 months

About the contract: The contract with Southwest Research Institute funds advanced development of a form of a drug called amyl nitrite that can be administered through the nose to treat injuries from exposure to cyanide. While other FDA-approved treatments for cyanide poisoning exist, the existing products must be administered intravenously by medical personnel. A metered-dose nasal spray formulation of amyl nitrite, however, could be administered quickly in the field, keeping affected patients alive until more definitive cyanide treatment can be provided at the hospital.

The contract with Southwest Research Institute will provide the efficacy data necessary to apply for FDA licensure of the drug for cyanide exposure when administered via metered nasal delivery.

Additional information: BARDA is seeking additional proposals for product candidates that potentially could treat illness and injury from acute and delayed chemical agents, as well as improved diagnostic tools to measure the dose a person has received after a chemical exposure. Proposals are accepted through the Broad Agency Announcement BARDA-CBRN-BAA-11-100-SOL-00009 at

Press Release: BARDA Supports Development of Drugs to Treat Chemical Injury

Procurement Announcement: Contract Award under BARDA-CBRN-BAA-10-100-SOL-00012

PHE Newsroom

Submit an Inquiry

Watch, Listen, Subscribe

Twitter  LinkedIn  Facebook  Instagram

Watch us on YouTube  Follow us on Flickr  Subcribe to our RSS  Subscribe to our email list

  • This page last reviewed: August 05, 2020